Hinge Health Reduces Imaging Visits by 60% for Chronic Back Pain Patients
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: Newsfilter
- Imaging Reduction: Participants in Hinge Health's chronic back pain program experienced a 60% reduction in imaging visits within three months compared to traditional PT care, significantly lowering unnecessary healthcare costs while enhancing patient care quality.
- Research Background: The study utilized data from over 100 million commercially insured lives from 2016 to 2021 across the U.S., emphasizing the effectiveness of digital MSK care in reducing high-cost services.
- Cost Control: By minimizing unnecessary imaging, Hinge Health not only reduces healthcare expenses but also improves overall patient health outcomes, highlighting the importance of evidence-based approaches in managing chronic back pain.
- Digital Care Advantages: Leveraging an AI-powered care model and wearable devices, Hinge Health delivers personalized, evidence-based care, further showcasing the potential of digital healthcare in enhancing patient experiences and reducing costs.
Analyst Views on HNGE
Wall Street analysts forecast HNGE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HNGE is 64.50 USD with a low forecast of 59.00 USD and a high forecast of 72.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 41.520
Low
59.00
Averages
64.50
High
72.00
Current: 41.520
Low
59.00
Averages
64.50
High
72.00
About HNGE
Hinge Health, Inc. leverages software, including artificial intelligence (AI), to largely automate care for joint and muscle health. The Company has designed its TrueMotion platform to address a spectrum of musculoskeletal (MSK) care from acute injury to chronic pain, to post-surgical rehabilitation. Members receive personalized and automated MSK care through its AI-powered motion tracking technology. It offers electrical nerve stimulation wearable device Enso, all designed and monitored by its AI-supported care team of licensed physical therapists, physicians, and board-certified health coaches. Its platform offers a range of support with multiple programs across many affected areas to provide a continuum of care from prevention to treatment of acute injury and chronic pain, as well as surgery decision support and post-surgical recovery. Enso delivers electrical nerve stimulation designed to provide non-addictive and non-invasive pain relief.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
